Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact

Biomedicine and Pharmacotherapy

Volumn 60, Issue 8, 2006, Pages 414-424

  Iervasi, A ^a   Iervasi, G ^a   Carpi, A ^b   Zucchelli, G C ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Differentiated thyroid cancer; Immunoassay; Thyroglobulin

Indexed keywords

EPITOPE; THYROGLOBULIN; THYROTROPIN;

AMBULATORY CARE; CANCER EPIDEMIOLOGY; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOASSAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY;

HUMANS; IMMUNOASSAY; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; REPRODUCIBILITY OF RESULTS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748913598     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.07.007     Document Type: Short Survey

References (71)

1. Pacini F., Fugazzola L., Lippi F., Ceccarelli C., Centoni R., Miccoli P., et al. Detection of thyroglobulin in fine needle aspirates of non thyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 74 (1992) 1401-1404
2. Cohen J.H., Ingbar S.H., and Braverman L.E. Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr. Rev. 10 (1989) 113-124
3. Mitchell M.L., and Hermos R.J. Measurement of thyroglobulin in newborn screening speciments from normal and hypothyroid infants. Clin. Endocrinol. (Oxf.) 42 (1995) 523-527
4. Smallridge R.C., De Keyser F.M., Van Herle A.J., Butkus N.E., and Wartfoskyl L. Thyroid iodine content and serum thyroglobulin: clues to the natural history of destruction-induced thyroiditis. J. Clin. Endocrinol. Metab. 62 (1986) 1213-1219
5. Schlumberger M. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338 (1998) 297-306
6. Mazzaferri E.L. NCCN. Thyroid carcinoma practice guidelines. Oncology 13 (1999) 391-442
7. Teppo L., and Hakulinen and Eurocare Working Group. Variation in survival of adult patients with thyroid cancer in Europe. Europ. J. Canc. 34 (1998) 2238-2252
8. Vanderpump M.P.J., Alexander L., Scarpello J.H.B., and Clayton R.N. An audit of management of thyroid cancer in a district general hospital. Clin. Endocrinol. (Oxf.) 48 (1998) 419-424
9. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics 2000. CA Cancer J. Clin. 50 (2000) 7-33
10. Kloss R.T., and Mazzaferri E.L. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurements predicts differentiated thyroid carcinoma metastases three to five. J. Clin. Endocrinol. Metab. 90 9 (2005) 5047-5057
11. Shah J.P., Kian K., Forastiere A., Garden A., Hoffman H.T., and Lee J.J. Cancer staging manual. 6th ed (2002), Springer-Verlag, New York 77-87
12. Schlumberger M., Berg G., Cohen O., Duntas L., Jamar F., Jarzab B., et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur. J. Endocrinol. 150 (2004) 105-112
13. Duren M., Siperstein A.E., Shen W., Duh Q.-Y., Morita E., and Clark O.H. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 126 (1999) 13-19
14. Girelli M.E., and De Vido D. Serum thyroglobulin measurement in differentiated thyroid cancer. Biomed. Pharm. 54 (2000) 330-333
15. Pacini F., and Pinchera A. Serum and tissue thyroglobulin measurement: clinical application in thyroid disease. Biochimie 81 (1999) 463-467
16. Mazzaferri E.L., and Kloss R.T. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 10 (2000) 767-778
17. Mazzaferri E.L., Robbins R.J., Spencer C.A., Braverman L.E., Pacini F., Wartofsky L., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 88 (2003) 1433-1441
18. Do Rosario P.W.S., Borges M.A.R., Fagundes T.A., Franco A.C.H.M., and Purish S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on throxin and negative ultrasound?. Clin. End. 62 (2005) 121-125
19. Demers LM, Spencer CA, editors. National Academy of Clinical Biochemistry. Laboratory support for the diagnosis and monitoring of thyroid disease. Available at http://www.nacb.org/lmpg/thyroid_lmpg_pub.stm (accessed Dec. 16, 2003), 2002. p. 55-65.
20. Schlumberger M., and Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 138 (1998) 249-252
21. Hardy K.J., Walker B.R., Lindsay R.S., Kennedy R.L., Seckl J.R., and Padfield P.L. Thyroid cancer management. Clin. Endocrinol. (Oxf.) 42 (1995) 651-655
22. Kendall-Taylor P on behalf of the Working Group. Guidelines for the management of thyroid cancer. Clin. Endocrinol. (Oxf.) 58 (2003) 400-402
23. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J. Clin. 47 (1997) 5-27
24. Hundahl S., Fleming I., Fremgen A., and Menk H. A national cancer data base report on 56,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83 (1998) 2638-2648
25. Haugen B., Pacini F., Reiners C., Schlumberger M., Ladenson P., Sherman S., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant of cancer. J. Clin. Endocrinol. Metab. 84 (1999) 3877-3885
26. Ladenson P., Braverman L., Mazzaferri E., Brucker-Davis F., Cooper D., Barber J., et al. Comparison of administration of recombinant human thyrotropin with withrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 337 (1997) 888-896
27. Robbins R.J., Tuttle R.M., Sharaf R.N., Larson S., Robbins H., Ghossein R., et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 86 (2001) 619-625
28. Spencer C.A., LoPresti J.S., Fatemi S., and Nicoloff J.T. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 9 (1999) 435-441
29. Mazzaferri E.L., and Kloss R.T. Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Endocrinol. Metab. 86 (2001) 1447-1463
30. Mazzaferri E.L., and Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J. Clin. Endocrinol. Metab. 87 (2002) 1490-1498
31. Robbins R.J., Chon J.T., Fleisher M., Larson S.M., and Tuttle M. Is the serum Thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?. J. Clin. Endocrinol. Metab. 87 (2002) 3242-3247
32. Pacini F., Capezzone M., Elisei R., Ceccarelli C., Taddei D., and Pinchera A. Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J. Clin. Endocrinol. Metab. 87 (2002) 1499-1501
33. Koh J.-M., Kim E.S., Ryu J.S., Hong S.J., Kim W.B., and Shong Y.K. Effects of therapeutic dose of 131-I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131-I whole-body scan: comparative study. Clin. Endocrinol. (Oxf.) 158 (2003) 421-425
34. Torlontano M., Crocetti U., D'Aloiso L., Bonfitto N., Di Giorgio A., Modoni S., et al. Serum thyroglobulin and 131-I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur. J. Endocrinol. 148 (2003) 19-24
35. Cailleux A.F., Baudin E., Travagli J.P., Ricard M., and Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J. Clin. Endocrinol. Metab. 85 (2000) 175-178
36. Ozata M., Suzuki S., Miyamoto T., Liu R.T., Fierro-Renoy F., and Degroot L.J. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 79 (1994) 98-105
37. Pacini F., Molinaro E., Lippi F., Castagna M.G., Agate L., Ceccarelli C., et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the post surgical follow-up of differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 86 (2001) 5686-5690
38. Cooper D.S., Doherty G.M., Haugen B.R., Kloss R.T., Lee S.L., Mandel S.J., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 2 (2006) 109-142
39. Torens J.I., and Burch H.B. Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol. Metab. Clin. North Am. 30 (2001) 429-467
40. Haugen B.R., Ridgway E.C.M.C., Laughlin B.A., and McDermott M.T. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 12 (2002) 37-43
41. Spencer C.A., Takeuchi M., and Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin. Chem. 42 (1996) 164-173
42. Spencer C.A., Takeuchi M., Kazarosyan M., Wang C.C., Guttler R.B., Singer P.A., et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83 (1998) 1121-1127
43. Clark P.M., and Beckett G. Can we measure serum thyroglobulin?. Ann. Clin. Biochem. 39 (2002) 196-202
44. Van Herle A.J., Klandorf H., and Uller R.P. A radioimmunoassay for serum rat thyroglobulin. Physiologie and pharmacological studies. J. Clin. Invest. 56 (1975) 1073-1081
45. Van Herle A.J., Uller R.P., Matthews N.I., and Brown J. Radioimmunoassay for measurement of thyroglobulin in human serum. J. Clin. Invest. 52 (1973) 1320-1327
46. Feldt-Rasmussen U., Profilis C., Colinet E., Schlumberger M., and Balck E. Purification and assessment of stability and homogeneity of human thyroglobulin reference material. Exp. Clin. Endocrinol. 102 (1994) 87-91
47. Ericsson U.B., Christensen S.B., and Thorell J.I. A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay. Clin. Immunol. Immunopathol. 37 (1985) 154-162
48. Spencer C.A., Bergoglio L.M., Kazarosyan M., Fatemi S., and LoPresti J.S. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90 10 (2005) 5566-5575
49. Zucchelli G.C., Pilo A., Masini S., Prontera C., and Ferdeghini M. Large between-laboratoty variability of thyroglobulin immunoassays: data collected in a collaborative study. J. Clin. Ligand Assay 19 (1996) 234-238
50. Mariotti S., Barbesino G., Caturegli P., Marino M., Manetti L., Pacini F., et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal. J. Clin. Endocrinol. Metab. 80 (1995) 468-472
51. Ochi Y., Hachiya T., Yoshimura M., Miyazaki T., and Majima T. Radioimmunoassay for estimation of thyroglobulin in human serum. Endocrinol. Jpn. 22 (1975) 351-356
52. Giovanella L., and Ceriani L. High-sensitivity human thyroglobulin (hTg) immunoradiometricassay in the follow-up of patients with differentiated thyroid cancer. Clin. Chem. Lab. Med. 40 (2002) 480-484
53. Wunderlich G., Zophel K., Crook L., Smith S., Rees Smith B., and Franke W.G. A high-sensitivity enzyme-linked immunosorbent assay for serum thyroglobulin. Thyroid 11 (2001) 819-824
54. Zophel K., Wunderlich G., and Rees Smith B. Serum thyroglobulin measurements with a high-sensitivity enzyme-linked immunosorbent assay: is there clinical benefit in patients with differentiated thyroid cancer?. Thyroid 13 (2003) 861-865
55. Iervasi A., Iervasi G., Bottoni A., Boni G., Annicchiarico C., Di Cecco P., et al. Diagnostic performance of a new high-sensitive thyroglobulin immunoassay. J. Endocrinol. 182 (2004) 287-294
56. Persoon A.C.M., Smit J.W.A., De Klerk J.M.H., and Links T.P. Clinical application of rh-TSH in differentiated thyroid cancer: the facts and the questions. Clin. Endocrinol. (Oxf.) 62 (2005) 258-262
57. Eustalia-Rutten C.F., Smit J.W., Romijn J.A., Van Der Kleij-Corssmit E.P.M., Pereira A.M., Stokkel M.P., et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. J. Clin. Endocrinol. 61 (2004) 61-74
58. Morgenthaler N.G., Froehlich J., Rendl J., Willnich M., Alonso C., Bergmann A., et al. Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clin. Chem. 48 (2002) 1077-1083
59. Pellegritti M., Scollo C., Regalbuto C., Attard M., Marozzi P., Vermiglio F., Violi M.A., Cianci M., Vigneri R., Pezzino V., and Squatnto S. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer with persistent disease and low thyroglobulin levels. Clin. Endocrinol. (Oxf) 58 (2003) 556-561
60. ® immunoassay. Clin. Chem. 50 (2004) A72-A73 [Abstract]
61. Amman A.J., and Hong R. Anti-antiserum antibody as a cause of double precipitin rings in immunoglobulin quantitation and its relation to milk precipitins. J. Immunol. 106 (1971) 567-569
62. Kricka L.J. Human anti-animal antibody interferences in immunological assays. Clin. Chem. 45 (1999) 942-956
63. Levinson S.S. Antibody multispecificity in immunoassay interference. Clin. Biochem. 25 (1992) 77-87
64. Preissner C.M., O'Kane D.J., Singh R.J., Morris J.C., and Grebe S.K.G. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 88 (2003) 3069-3074
65. Prince A.M., Brotman B., Jass D., and Ikram H. Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis B antigen. Lancet 16 1 (1973) 1346-1350
66. Boscato L.M., and Stuart M.C. Heterophilic antibodies: a problem for all immunoassays. Clin. Chem. 34 (1988) 27-33
67. Boscato L.M., and Stuart M.C. Incidence and specificity of interference in two-site immunoassays. Clin. Chem. 32 (1986) 1491-1495
68. Kohse K.P., and Wisser H. Antibodies as a source of analytical errors. J. Clin. Chem. Clin. Biochem. 28 (1990) 881-892
69. Thompson R.J., Jackson A.P., and Langiois N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects-incidence, species specificity, and effects on two-site assay for creatine Kinase-MB isoenzyme. Clin. Chem. 32 (1986) 476-481
70. Hedenborg G., Petterson T., and Carlstrom A. Heterophilic antibodies causing falsely raised thyroid-stimulating hormon results. Lancet ii (1979) 755
71. Lipp R.W., Passath A., and Leb G. The incidence of non-iatrogenic human anti mouse antibodies and their possible clinical relevance. Eur. J. Nucl. Med. 18 (1991) 996-997